ABVC BioPharma regains Nasdaq minimum bid price compliance; reports 234% revenue growth in FY2024

ABVC BIOPHARMA, INC.

Regained compliance after maintaining $1.00 bid price for 10 consecutive days through May 12, 2025.
FY2024 revenue increased 234% YoY; operating expenses reduced 21%; EPS improved 77%.
Secured three licensing partnerships with potential $7M upfront and up to $660M in milestones.
Received approximately $0.5M in upfront payments in FY2025 year-to-date.
Preliminary discussions underway with pharma and AI firms for co-developing Phase III-ready MDD and ADHD candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.